Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

Summary

This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance, the omega-3 fatty acid, eicosapentaenoic acid (EPA).

Timeline

Start

2006-11

Primary completion

2008-04

Completion

2008-04

Outcome

Met primary endpoint

registry 2g/Day Eicosapentaenoic Acid (EPA) vs Placebo; p = 0.005; Mean Difference (Net) -1.06 (95% CI -1.78 to -0.35); ANCOVA NCT00510692 ↗

Publications

• West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010 Jul;59(7):918-25. doi: 10.1136/gut.2009.200642. Epub 2010 Mar 26.

Drugs

Indications